What question did this study set out to answer?

To review the diagnostic and therapeutic utility of incorporating functional proliferation and survival biomarkers (Ki-67 and Bcl-2) into multiparameter flow cytometry workflows for myelodysplastic syndromes (MDS).

August 19, 2026CancersOpen Access

Functional Characterization of Myelodysplastic Syndrome by Multiparameter Flow Cytometry: The Clinical Synergy Between Ki-67 and Bcl-2 and Their Potential Role in Diagnostics and Personalized Therapy

View Full Paper

Ask AI

Bookmark

Authors

SWSixuan J. Wang RMRinaldo A. J. N. van Meel SMStefan G.C. Mestrum

Discussion

Member takes

Overview

Systematic review demonstrates improved diagnostic sensitivity and targeted therapy stratification in myelodysplastic neoplasms using functional biomarkers, suggesting enhanced clinical management.

Key Points

To review the diagnostic and therapeutic utility of incorporating functional proliferation and survival biomarkers (Ki-67 and Bcl-2) into multiparameter flow cytometry workflows for myelodysplastic syndromes (MDS).
Synthesized literature on high-dimensional multiparameter flow cytometry (MFC) and maturation continuum analysis across myeloid, erythroid, and monocytic lineages.
Evaluated diagnostic improvements when adding the erythroid Ki-67 proliferation index to the standard Ogata score.
Analyzed the Bcl-2:Ki-67 ratio as a functional biomarker for disease biology and predictive stratification for targeted therapies such as venetoclax.
Adding the erythroid Ki-67 proliferation index to the standard Ogata score increased overall MDS diagnostic sensitivity from 66% to 90% and low-grade MDS sensitivity from 56% to 91%, while maintaining 100% specificity.
A reduced erythroid Ki-67 index (≤28%) independently predicted patient transfusion dependence within 1 year.
A high Bcl-2:Ki-67 ratio identified a quiescent, chemotherapy-refractory cell population well-suited for targeted Bcl-2 inhibition with venetoclax.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a85637603308d306e2d6910 https://doi.org/10.3390/cancers18162648

View Full Paper

Ask AI

Bookmark

August 19, 2026CancersOpen Access

Functional Characterization of Myelodysplastic Syndrome by Multiparameter Flow Cytometry: The Clinical Synergy Between Ki-67 and Bcl-2 and Their Potential Role in Diagnostics and Personalized Therapy

View Full Paper

Ask AI

Bookmark

Authors

SWSixuan J. Wang RMRinaldo A. J. N. van Meel SMStefan G.C. Mestrum

Discussion

Member takes

Overview

Systematic review demonstrates improved diagnostic sensitivity and targeted therapy stratification in myelodysplastic neoplasms using functional biomarkers, suggesting enhanced clinical management.

Key Points

To review the diagnostic and therapeutic utility of incorporating functional proliferation and survival biomarkers (Ki-67 and Bcl-2) into multiparameter flow cytometry workflows for myelodysplastic syndromes (MDS).
Synthesized literature on high-dimensional multiparameter flow cytometry (MFC) and maturation continuum analysis across myeloid, erythroid, and monocytic lineages.
Evaluated diagnostic improvements when adding the erythroid Ki-67 proliferation index to the standard Ogata score.
Analyzed the Bcl-2:Ki-67 ratio as a functional biomarker for disease biology and predictive stratification for targeted therapies such as venetoclax.
Adding the erythroid Ki-67 proliferation index to the standard Ogata score increased overall MDS diagnostic sensitivity from 66% to 90% and low-grade MDS sensitivity from 56% to 91%, while maintaining 100% specificity.
A reduced erythroid Ki-67 index (≤28%) independently predicted patient transfusion dependence within 1 year.
A high Bcl-2:Ki-67 ratio identified a quiescent, chemotherapy-refractory cell population well-suited for targeted Bcl-2 inhibition with venetoclax.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a85637603308d306e2d6910 https://doi.org/10.3390/cancers18162648

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark